HIF-1α and VEGF are considered as potential targets for cancer therapy because they play an important role in the progression of many types of cancer, including leukemia, and are associated with resistance to therapy and poor prognosis [10]–[13], [43]–[45]. Here, VEGFA is linked to leukemia.